Myeloma, Multiple Clinical Trials
- Vaccine Therapy Plus GM-CSF in Treating Patients With Multiple Myeloma Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00002787 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy and Interferon alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
ClinicalTrials.gov Identifier: NCT00002599 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00088855 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Bortezomib in Combination with CC-5013 in Patients with Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00153933 - Active, not recruiting
Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple Myeloma
- Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002556 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002678 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00098475 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Dexamethasone With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00064038 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006184 - Recruiting
Multiple Myeloma
- Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
ClinicalTrials.gov Identifier: NCT00002850 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection
- Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Phase III Randomized Study of Melphalan With or Without Holmium Ho 166 DOTMP Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00008229 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049673 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
ClinicalTrials.gov Identifier: NCT00048464 - Active, not recruiting
Multiple Myeloma
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00109902 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00080405 - Active, not recruiting
Multiple Myeloma
- Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00040937 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006219 - Active, not recruiting
Multiple Myeloma
- Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00114101 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00095680 - Active, not recruiting
Multiple Myeloma
- High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
ClinicalTrials.gov Identifier: NCT00065351 - Active, not recruiting
Multiple Myeloma
- VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients with Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00111319 - Active, not recruiting
Multiple Myeloma
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00253578 - Recruiting
Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
- Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00024466 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00087867 - Active, not recruiting
Multiple Myeloma
- Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
- Antineoplaston Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003511 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00021359 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Phase I/II Study of Safety & Efficacy of Perifosine & Bortezomib With or Without Dexamethasone for Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00401011 - Recruiting
Multiple Myeloma; Relapsed or Refractory Multiple Myeloma
- Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002653 - Active, not recruiting
Multiple Myeloma
- Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- A Multicenter, Open-Label, Single-Arm, Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00179647 - Recruiting
Multiple Myeloma
- Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002548 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00113919 - Active, not recruiting
Multiple Myeloma
- Thal/Dex (Thalidomide and Dexamethasone) vs. Dd-T (Doxil, Dexamethasone and Thalidomide) in Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00097981 - Active, not recruiting
Multiple Myeloma
- Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004088 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124813 - Recruiting
Multiple Myeloma
- Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00344422 - Active, not recruiting
M-Protein; Multiple Myeloma; Myeloma; Myeloma Proteins
- R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Beta Alethine in Treating Patients With Myeloma
ClinicalTrials.gov Identifier: NCT00006466 - Active, not recruiting
monoclonal gammopathy of undetermined significance; stage I multiple myeloma; stage II multiple myeloma; extramedullary plasmacytoma; ...
- Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00483262 - Recruiting
Multiple Myeloma; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
- Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00057564 - Active, not recruiting
Multiple Myeloma
- Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Phase I/II Study of hLL1 in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00421525 - Recruiting
Multiple Myeloma; Myeloma, Plasma-Cell; Plasmacytoma
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00090493 - Recruiting
Multiple Myeloma
- Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00084747 - Recruiting
stage II multiple myeloma; stage III multiple myeloma
- Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00075881 - Active, not recruiting
stage III multiple myeloma
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003146 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00056160 - Active, not recruiting
Multiple Myeloma
- Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00103506 - Active, not recruiting
Multiple Myeloma
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00151203 - Active, not recruiting
Multiple Myeloma
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00186238 - Active, not recruiting
Multiple Myeloma
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
ClinicalTrials.gov Identifier: NCT00186316 - Active, not recruiting
Multiple Myeloma
- Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00111813 - Recruiting
Multiple Myeloma
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00317811 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
ClinicalTrials.gov Identifier: NCT00257114 - Active, not recruiting
Multiple Myeloma
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028886 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma
- Bortezomib (Velcade) in Patients with Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00153920 - Active, not recruiting
Multiple Myeloma
- The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00207805 - Active, not recruiting
Multiple Myeloma
- A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00420849 - Active, not recruiting
Multiple Myeloma
- Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00054353 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00193557 - Active, not recruiting
Multiple Myeloma
- Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00327249 - Active, not recruiting
Multiple Myeloma
- Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00382694 - Active, not recruiting
Multiple Myeloma
- Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
ClinicalTrials.gov Identifier: NCT00388635 - Active, not recruiting
Multiple Myeloma
- Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00014339 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; Quality of Life
- FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00066638 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- UARK 2003-41: A Study of High-Dose Density Therapy in Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00113932 - Active, not recruiting
Multiple Myeloma
- A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
ClinicalTrials.gov Identifier: NCT00091624 - Active, not recruiting
Multiple Myeloma
- Safety Study of IPI-504 in Patients with Relapsed and Relapsed Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00113204 - Active, not recruiting
Multiple Myeloma
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00116961 - Active, not recruiting
Multiple Myeloma
- A Pilot Study of Combination Therapy with VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00135187 - Active, not recruiting
Multiple Myeloma
- Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
ClinicalTrials.gov Identifier: NCT00004040 - Active, not recruiting
stage II chronic lymphocytic leukemia; stage I multiple myeloma; stage II multiple myeloma; stage IV chronic lymphocytic leukemia; ...
- Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028600 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00478777 - Active, not recruiting
Relapsed or Refractory Multiple Myeloma
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00193544 - Active, not recruiting
Multiple Myeloma
- Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00256880 - Active, not recruiting
Multiple Myeloma
- Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00375791 - Active, not recruiting
Multiple Myeloma
- Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00263484 - Recruiting
Multiple Myeloma
- Arsenic Trioxide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00039754 - Active, not recruiting
Multiple Myeloma
- An Invstigational Drug, PD 0332991, is Being Studied in Combination With Velcade and Dexamethasone in Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment for Multiple Myeloma.
ClinicalTrials.gov Identifier: NCT00555906 - Not yet recruiting
Multiple Myeloma
- Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
ClinicalTrials.gov Identifier: NCT00200668 - Not yet recruiting
Multiple Myeloma
- Study of Combination PS-341 and Thalidomide in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00083460 - Active, not recruiting
Multiple Myeloma
- Stem Cell Transplant for Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00386568 - Active, not recruiting
Multiple Myeloma
[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
| 
Not Signed In - 
email this page
print this page
bookmark this page
feedback on this page
